GlassScriptPhysician profile
Robert A Taylor
NPI 1487643193
$198,389.68
in general payments reported to CMS, 2019-2025
26 companies · $47K in 2025
The $47K reported for 2025 was more than what 95% of Neurological Surgery providers received nationally (typical 2025 total: $604).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $15K · 2020: $24K · 2021: $37K · 2022: $21K · 2023: $25K · 2024: $28K · 2025: $47K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $98K · Food and Beverage: $3,203.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $97,537.50 |
| Food and Beverage | $3,202.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $186,816.83 | 2019-2025 | Clinical Trial Product, Watchman Access System |
| Balt USA, LLC | $4,976.08 | 2019-2022 | |
| Stryker Corporation | $2,112.30 | 2019-2025 | Surpass Evolve, Target, Axs Vecta 71 |
| Microvention, INC. | $1,012.45 | 2019-2025 | Sofia 6f-131cm Str, Web Aneurysm Embolization System |
| Penumbra, INC. | $953.77 | 2019-2025 | Penumbra System, Red 72, Benchmark |
| Depuy Synthes Sales INC. | $393.13 | 2019-2024 | Trufill |
| Abbvie INC. | $377.62 | 2024-2025 | |
| Cardiva Medical, INC. | $258.79 | 2023 | Cardiva Vascade Mvp Vvcs 6-12f, Cardiva Vascade 5f Vcs |
| Portola Pharmaceuticals, LLC | $233.41 | 2019 | |
| Medtronic, INC. | $210.43 | 2025 | Pipeline |
| Astrazeneca Pharmaceuticals LP | $167.33 | 2021-2022 | |
| Imperative Care, INC | $155.87 | 2020-2024 | Zoom Reperfusion Catheter |
| Medtronic USA, INC. | $129.50 | 2019 | |
| Eisai INC. | $121.31 | 2025 | |
| Amgen INC. | $86.38 | 2022-2025 | Prolia, Evenity |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alexion Pharmaceuticals, INC. | $70.03 | 2022 | |
| Route 92 Medical, INC. | $49.80 | 2025 | |
| Paratek Pharmaceuticals, INC. | $43.62 | 2021 | |
| Merck Sharp & Dohme LLC | $37.94 | 2021 | |
| Shionogi INC | $34.24 | 2022 | |
| Nabriva Therapeutics, Plc | $31.33 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $31.16 | 2022 | |
| Pulmonx Corporation | $25.20 | 2023 | Pulmonx Chartis Tablet Console, Zephyr Delivery Catheter, Zephyr Endobronchial Valve |
| United Therapeutics Corporation | $23.17 | 2022 | |
| Janssen Pharmaceuticals, INC | $22.41 | 2021 | |
| Siemens Medical Solutions USA, INC. | $15.58 | 2023 | Corpath Imaging System |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Taylor listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.